Format

Send to

Choose Destination
Cell Rep. 2014 Jul 10;8(1):40-9. doi: 10.1016/j.celrep.2014.05.036. Epub 2014 Jun 19.

Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer.

Author information

1
Department of Oncological Sciences, University of Utah and Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
2
Department of Surgery, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA.
3
ARUP Laboratories, Department of Pathology, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA.
4
Department of Oncological Sciences, University of Utah and Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. Electronic address: trudy.oliver@hci.utah.edu.

Abstract

Squamous cell carcinoma (SCC) of the lung is the second most common subtype of lung cancer. With limited treatment options, the 5-year survival rate of SCC is only 15%. Although genomic alterations in SCC have been characterized, identifying the alterations that drive SCC is critical for improving treatment strategies. Mouse models of SCC are currently limited. Using lentiviral delivery of Sox2 specifically to the mouse lung, we tested the ability of Sox2 to promote tumorigenesis in multiple tumor suppressor backgrounds. Expression of Sox2, frequently amplified in human SCC, specifically cooperates with loss of Lkb1 to promote squamous lung tumors. Mouse tumors exhibit characteristic histopathology and biomarker expression similar to human SCC. They also mimic human SCCs by activation of therapeutically relevant pathways including STAT and mTOR. This model may be utilized to test the contribution of additional driver alterations in SCC, as well as for preclinical drug discovery.

PMID:
24953650
PMCID:
PMC4410849
DOI:
10.1016/j.celrep.2014.05.036
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center